Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.
The Vinnie from Queens panel weighs in on the NFL draft and the NBA playoffs.
AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a clai...
Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...
The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pha...
Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.
High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...
Amgen (NASDAQ:AMGN) said Tuesday its first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.The company reported net income o...
Novartis CEO Joe Jimenez on his company’s corporate transformation and focus on pharmaceuticals, eyecare and generics.
Altaira senior managing director Ralph Acampora on the Novartis M&A news and the landscape for pharmaceuticals.
Altaira senior managing director Ralph Acampora on the Dow Transports and the ‘forgotten’ stocks to watch.
FBN’s Maria Bartiromo on U.S. futures and the $25 billion in Novartis deals.
WSJ Europe markets editor Charles Forelle says big pharma deals are boosting European markets.
InterDigital CEO William Merritt talks business in the technology industry.
FBN’s David Asman on Novartis ’ partnership with Google, Facebook’s plans to track users’ TV habits and Morgan Stanley’s report on the potential Apple iWatch.
Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.
Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.
Ford CEO Alan Mulally on technology in cars, the leadership transition at the automaker and balancing his work and family life.
Markets.com chief economist Bill Hubard with the latest on the European markets.
John Eade of the Argus Research Company and Mizuho chief investments strategist Carmine Grigoli discuss the M&A market and where the growth is.